Merck KGaA Valuation
Is MRCK undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of MRCK when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: MRCK (€141.45) is trading below our estimate of fair value (€303.86)
Significantly Below Fair Value: MRCK is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for MRCK?
Key metric: As MRCK is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.
| What is MRCK's PE Ratio? | |
|---|---|
| PE Ratio | 22.9x |
| Earnings | €2.70b |
| Market Cap | €61.63b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.3x |
| Enterprise Value/EBITDA | 13.6x |
| PEG Ratio | 2.1x |
Price to Earnings Ratio vs Peers
How does MRCK's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30.1x | ||
4519 Chugai Pharmaceutical | 26.7x | 6.2% | JP¥10.3t |
GSK GSK | 21.8x | 21.9% | UK£54.8b |
ZTS Zoetis | 32.9x | 9.9% | US$79.8b |
SUNPHARMA Sun Pharmaceutical Industries | 39x | 12.7% | ₹4.3t |
MRCK Merck KGaA | 22.9x | 10.9% | €61.6b |
Price-To-Earnings vs Peers: MRCK is good value based on its Price-To-Earnings Ratio (22.9x) compared to the peer average (30.1x).
Price to Earnings Ratio vs Industry
How does MRCK's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?
| 1 Company | Price / Earnings | Estimated Growth | Market Cap |
|---|---|---|---|
| 1 Company | Estimated Growth | Market Cap | |
|---|---|---|---|
Price-To-Earnings vs Industry: MRCK is expensive based on its Price-To-Earnings Ratio (22.9x) compared to the European Pharmaceuticals industry average (20.2x).
Price to Earnings Ratio vs Fair Ratio
What is MRCK's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 22.9x |
| Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate MRCK's Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | €141.45 | €184.38 +30.3% | 6.1% | €200.00 | €160.00 | n/a | 16 |
| Nov ’25 | €154.40 | €185.50 +20.1% | 5.6% | €200.00 | €160.00 | n/a | 16 |
| Oct ’25 | €155.60 | €187.18 +20.3% | 5.2% | €205.00 | €165.00 | n/a | 17 |
| Sep ’25 | €176.10 | €185.94 +5.6% | 5.0% | €200.00 | €165.00 | n/a | 16 |
| Aug ’25 | €168.00 | €183.00 +8.9% | 5.9% | €200.00 | €165.00 | n/a | 16 |
| Jul ’25 | €152.35 | €184.44 +21.1% | 6.1% | €200.00 | €160.00 | n/a | 16 |
| Jun ’25 | €167.20 | €184.81 +10.5% | 6.9% | €205.00 | €160.00 | n/a | 16 |
| May ’25 | €149.00 | €182.00 +22.1% | 6.9% | €200.00 | €155.00 | n/a | 16 |
| Apr ’25 | €163.75 | €181.63 +10.9% | 7.6% | €210.00 | €155.00 | n/a | 16 |
| Mar ’25 | €158.20 | €179.25 +13.3% | 7.8% | €200.00 | €155.00 | n/a | 16 |
| Feb ’25 | €149.40 | €181.56 +21.5% | 9.3% | €215.00 | €150.00 | n/a | 16 |
| Jan ’25 | €142.90 | €184.75 +29.3% | 9.5% | €215.00 | €150.00 | n/a | 16 |
| Dec ’24 | €158.80 | €190.06 +19.7% | 8.4% | €220.00 | €166.00 | n/a | 16 |
| Nov ’24 | €143.55 | €188.88 +31.6% | 8.5% | €220.00 | €166.00 | €154.40 | 16 |
| Oct ’24 | €158.05 | €197.56 +25.0% | 5.9% | €220.00 | €171.00 | €155.60 | 16 |
| Sep ’24 | €167.35 | €195.24 +16.7% | 5.9% | €220.00 | €171.00 | €176.10 | 17 |
| Aug ’24 | €160.30 | €197.95 +23.5% | 6.2% | €220.00 | €171.00 | €168.00 | 17 |
| Jul ’24 | €151.30 | €204.56 +35.2% | 6.0% | €220.00 | €171.00 | €152.35 | 15 |
| Jun ’24 | €164.10 | €204.24 +24.5% | 6.2% | €225.00 | €171.00 | €167.20 | 16 |
| May ’24 | €162.20 | €206.59 +27.4% | 8.7% | €250.00 | €158.00 | €149.00 | 16 |
| Apr ’24 | €171.85 | €207.53 +20.8% | 8.8% | €250.00 | €158.00 | €163.75 | 16 |
| Mar ’24 | €176.65 | €208.74 +18.2% | 9.7% | €250.00 | €158.00 | €158.20 | 17 |
| Feb ’24 | €182.35 | €208.91 +14.6% | 9.5% | €250.00 | €158.00 | €149.40 | 17 |
| Jan ’24 | €181.75 | €207.21 +14.0% | 9.3% | €250.00 | €158.00 | €142.90 | 17 |
| Dec ’23 | €176.60 | €205.86 +16.6% | 9.6% | €250.00 | €158.00 | €158.80 | 18 |
| Nov ’23 | €163.30 | €203.97 +24.9% | 10.7% | €250.00 | €146.00 | €143.55 | 18 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
Almirall
€1.8b
A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.
ALM
€8.40
7D
-0.5%
1Y
0%
Teva Pharmaceutical Industries
US$19.4b
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.
TEVA
US$16.30
7D
4.2%
1Y
85.6%
Bayer
€19.5b
Operates as a life science company worldwide.
BAYN
€19.77
7D
-3.7%
1Y
-39.4%